



(51) International Patent Classification:

A61J 1/20 (2006.01) B65B 55/00 (2006.01)
A61J 1/06 (2006.01) B65B 3/04 (2006.01)

(21) International Application Number:

PCT/IB2017/001183

(22) International Filing Date:

03 August 2017 (03.08.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/371,196 04 August 2016 (04.08.2016) US
15/453,615 08 March 2017 (08.03.2017) US

(71) Applicant: **VANRX PHARMASYSTEMS INC**
[CA/CA]; 3811 North Fraser Way #200, Burnaby, BC V5J 5J2 (CA).

(72) Inventors: **PROCYSHYN, Christopher**; C/o Vanrx Pharmsystems Inc, 3811 North Fraser Way #200, Burnaby, BC V5J 5J2 (CA). **NIANG, Juvenal**; C/o Vanrx Pharmsystems Inc, 3811 North Fraser Way #200, Burnaby, BC V5J 5J2 (CA). **SENGER, John**; C/o Vanrx Pharmsystems Inc, 3811 North Fraser Way #200, Burnaby, BC V5J 5J2 (CA).

CICHY, Marcin; C/o Vanrx Pharmsystems Inc, 3811 North Fraser Way #200, Burnaby, BC V5J 5J2 (CA).

(74) Agent: **WANG, Katie**; Sharipo Cohen LLP, Suite 830, 555 Legget Drive, Ottawa, ON K2K 2X3 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: APPARATUS AND METHOD FOR ASEPTICALLY FILLING PHARMACEUTICAL CONTAINERS WITH A PHARMACEUTICAL FLUID




Fig. 1

(57) Abstract: Systems and methods for aseptically filling pharmaceutical containers with pharmaceutical fluid are disclosed. In one general aspect, these are based on an aseptically sealable chamber that includes a transfer wall to which pre-sealed pharmaceutical source and receiving containers are mounted aseptically. A robotic arm and a syringe store are disposed within the chamber along with a sterilizing facility for establishing in the chamber an aseptic condition. The robotic arm can grip and operate syringes to inject and/or extract pharmaceutical products from the containers by piercing their closures with the needles of the syringes.

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

APPARATUS AND METHOD FOR ASEPTICALLY FILLING PHARMACEUTICAL
CONTAINERS WITH A PHARMACEUTICAL FLUID

BACKGROUND OF THE INVENTION

This application claims priority to US Provisional Application No. 62/371,196, filed August 4, 2017, which is herein incorporated by reference.

Field of the Invention

[0001] This present invention relates to the medical field and more particularly to apparatus and associated methods for sterilization of and sterile handling of pharmaceutical materials and containers for pharmaceuticals, including bringing pharmaceuticals into form for administration to medical or veterinary patients. In one aspect, it relates to the programmed and automatic operation of such apparatus.

Background

[0002] The subject of filling pharmaceuticals into pharmaceutical containers is a major aspect of the Pharmaceuticals Industry. The subject is heavily controlled by various governmental and official bodies in various countries. Technologically, the subject is a challenge in that the pharmaceutical products need to be filled into the containers under very strict aseptic conditions. Very specific procedures are specified for this task to a degree that makes the handling of pharmaceuticals profoundly different from the handling of any other industrial product, including specifically semiconductors, which also demand extreme and consistent environmental conditions. Indeed, the parallels between the handling of

semiconductors in semiconductor “clean laboratories” and the handling of pharmaceuticals in aseptic isolators are superficial. They share the use of such “clean laboratories”, but there is no inherent aseptic requirement associated with semiconductor manufacture.

[0003] The filling of pharmaceutical containers with fluid pharmaceuticals specifically requires the aseptic handling of both the containers and the fluid pharmaceutical itself. This leads to complex mechanisms and procedures, many of which may be automated to one degree or another. Often, the production equipment for fluid pharmaceutical handling is bulky and expensive. This creates a problem for smaller operations, particularly in the small scale production and development environments. As the field has developed, the need for smaller, more compact equipment, particularly in the filling and dispensing of fluid pharmaceuticals has become evident.

[0004] The present invention addresses the need for compact small scale filling and dispensing of fluid pharmaceuticals.

SUMMARY OF THE INVENTION

[0005] In one general aspect, the invention features a system for aseptically filling pharmaceutical containers with pharmaceutical fluid that includes an aseptically sealable chamber. The aseptically sealable chamber includes a transfer wall with openings that each provide a sealing surface that is aseptically sealable to a container. A robotic arm is disposed within the sealable chamber and has a range of motion that allows it to move a fluid transfer conduit to each of the openings. The system also includes a fluid transfer actuator to drive fluid through the fluid transfer conduit, a sterilizing facility for establishing an aseptic condition within the sealable chamber, and a controller. The controller includes three-dimensional arm control logic to move the fluid transfer conduit to a selected container that sealably passes through one of the openings. It also includes fluid transfer actuation logic to operate the fluid transfer actuator to transfer fluid between a fluid transfer vessel and the selected container.

[0006] In preferred embodiments, the fluid transfer conduit can be a syringe needle mounted on a syringe that includes a body and a plunger, with the fluid transfer actuator being a linear actuator that moves the plunger relative to the body. The system can further include at least one container with a pierceable closure sealably passing through one of the openings with the pierceable closure positioned inside the sealable chamber and with the three-dimensional arm control logic being operative to cause the syringe needle to pierce the pierceable closure. The three-dimensional arm control logic and the fluid transfer actuation logic can be operative to transfer fluids from one container to another. The system can further include a syringe store disposed in the interior of the sealable chamber, with the three-dimensional arm control logic being operative to transfer syringes to and from the syringe store. The robotic arm can be an articulated robotic arm. The sealable chamber can be capable of being operated under a positive pressure when sealed.

[0007] In another general aspect, the invention features a method for filling pharmaceutical containers with a fluid pharmaceutical product. This method includes providing an aseptically sealable chamber comprising a robotic arm and a transfer wall capable of having aseptically mounted thereto a plurality of pharmaceutical containers pre-sealed with pierceable closures. The aseptically sealable chamber is capable of maintaining an aseptic condition within an interior of the sealable chamber when the pharmaceutical containers are mounted to the transfer wall. The method also includes aseptically mounting to the transfer wall a plurality of pharmaceutical containers aseptically pre-sealed with corresponding pierceable pharmaceutical container closures, with the mounting of the plurality of pharmaceutical containers comprising mounting the plurality of pharmaceutical containers in locations and orientations wherein the corresponding pierceable pharmaceutical container closures are penetrable from within the interior of the sealable chamber. The sealable chamber is provided with a first pharmaceutical syringe comprising a first syringe needle, the chamber is aseptically sealed, and an aseptic condition is established within the interior of the sealable chamber and on all portions of the plurality of pharmaceutical containers exposed to the interior of the sealable chamber. A portion of the first fluid pharmaceutical product can then be transferred between the first syringe and at least one of the plurality of

pharmaceutical containers through the corresponding pierceable pharmaceutical container closure via the first syringe needle.

[0008] In preferred embodiments the transferring can comprise piercing the corresponding pierceable pharmaceutical container closure with the first syringe needle. The transferring can comprise operating the robotic arm. Providing an aseptically sealable chamber comprising a robotic arm can comprise providing an aseptically sealable chamber comprising an articulated robotic arm with the transferring comprising operating the articulated robotic arm. The transferring can include injecting a portion of the first pharmaceutical product into the one of the plurality of pharmaceutical containers, and providing within the sealable chamber the first pharmaceutical syringe containing the first fluid pharmaceutical product can comprise: aseptically mounting to the transfer wall a first source pharmaceutical container aseptically pre-sealed with a corresponding pierceable first pharmaceutical container closure, with the mounting of the first source pharmaceutical container comprising disposing the first source pharmaceutical container in a location and orientation wherein the first pharmaceutical container closure is penetrable from within the interior of the sealable chamber, piercing the closure of the first source pharmaceutical container with the first syringe needle, and extracting a portion of the first fluid pharmaceutical product from the first source pharmaceutical container into the first pharmaceutical syringe. At least one of the aseptically sealing, the establishing an aseptic condition, the transferring, and the extracting a portion of the first fluid pharmaceutical product can be performed automatically. The method can further comprise establishing within the sealable chamber a positive atmospheric pressure. The establishing within the sealable chamber a positive atmospheric pressure can be performed automatically after the aseptically sealing the sealable chamber. The method can further comprise injecting a portion of a second fluid pharmaceutical product from a second syringe into the at least one of the plurality of pharmaceutical containers through the corresponding pierceable pharmaceutical container closure via a second syringe needle. The providing an aseptically sealable chamber can comprise providing an aseptically sealable chamber comprising a syringe store, with the second syringe being prepared by: aseptically mounting to the transfer wall a second source pharmaceutical container aseptically pre-sealed

with a corresponding pierceable second pharmaceutical container closure and containing the second fluid pharmaceutical, with the mounting of the second source pharmaceutical container comprising disposing the second source pharmaceutical container in a location and orientation wherein the second pharmaceutical container closure is penetrable from within the interior of the sealable chamber, operating the robotic arm to place the first syringe in the syringe store, operating the robotic arm to obtain from the syringe store the second pharmaceutical syringe comprising the second syringe needle, operating the robotic arm to pierce the closure of the second source pharmaceutical container with the second syringe needle, and operating the robotic arm to extract a portion of the second fluid pharmaceutical product from the second source pharmaceutical container into the syringe. The establishing an aseptic condition can comprise treating the interior of the sealable chamber and all portions of the at least one pharmaceutical container exposed to the interior of the sealable chamber with at least one of heated water vapor, gaseous hydrogen peroxide, ozone, nitrogen dioxide, ethylene oxide, and glutaraldehyde vapor.

[0009] In a further general aspect, the invention features a system for aseptically filling pharmaceutical containers with pharmaceutical fluid that includes means for receiving a plurality of containers while exposing accessible parts of the containers, means for transferring pharmaceutical fluid to and from the containers through the accessible parts of the containers, and means for reaching the accessible parts of the received containers with the means for transferring. The system also includes means for controlling the means for reaching and the means for transferring, means for together isolating the exposed parts of the containers, the means for reaching, and the means for transferring, and means for sterilizing the exposed parts of the containers, the means for reaching, and the means for transferring.

[00010] Systems according to the invention can provide a compact and cost-effective way to automatically perform a wide variety of pharmaceutical filling operations in an aseptic environment using readily available pre-sterilized containers with pierceable closures.

BRIEF DESCRIPTION OF THE DRAWINGS

[00011] The above mentioned and other features and objects of this invention, and the manner of attaining them, will become more apparent and the invention itself will be better understood by reference to the following description of an embodiment of the invention taken in conjunction with the accompanying drawings, wherein:

[00012] FIG. 1 is a drawing of a first embodiment of an apparatus for filling pharmaceutical containers with a pharmaceutical fluid product.

[00013] FIG. 2(a) is an exploded view of one example aseptic sealing structure for sealing a pharmaceutical container to a transfer wall between an aseptic interior volume and an ambient volume of an apparatus for aseptically filling pharmaceutical containers with a pharmaceutical fluid.

[00014] FIG. 2(b) is a view of the example aseptic sealing structure of FIG. 2(a) when assembled.

[00015] FIG. 2(c) is a cross-sectional view of the assembled aseptic sealing structure of FIG. 2(b)

[00016] FIG. 2(d) is a drawing of an arrangement for aseptically sealing a plurality of pharmaceutical containers to a sealing plate that may be aseptically sealable to a transfer wall between an aseptic interior volume and an ambient volume of an apparatus for aseptically filling pharmaceutical containers with a pharmaceutical fluid.

[00017] FIG. 2(e) is a drawing of one example aseptic sealing structure for sealing an intravenous bag pharmaceutical container to a transfer wall between an aseptic interior volume

and an ambient volume of an apparatus for aseptically filling pharmaceutical containers with a pharmaceutical fluid.

[00018] FIG. 2(f) is a cross-sectional view of the structure of FIG. 2(e)

[00019] FIG. 2(g) is a drawing of an arrangement for aseptically sealing a plurality of intravenous bag pharmaceutical containers to a sealing plate that may be aseptically sealable to a transfer wall between an aseptic interior volume and an ambient volume of an apparatus for aseptically filling pharmaceutical containers with a pharmaceutical fluid.

[00020] FIG.3 is a drawing of a second embodiment of an apparatus for filling pharmaceutical containers with a pharmaceutical fluid product.

[00021] FIG.4 is a flow diagram of a method for filling a pharmaceutical container with a fluid pharmaceutical product.

[00022] Corresponding reference characters indicate corresponding parts throughout the several views. Although the drawings represent embodiments of the present invention, the drawings are not necessarily to scale and certain features may be exaggerated in order to better illustrate and explain the present invention. The flow charts are also representative in nature, and actual embodiments of the invention may include further features or steps not shown in the drawings. The exemplifications set out herein illustrate embodiments of the invention, in one or more forms, and such exemplifications are not to be construed as limiting the scope of the invention in any manner.

DESCRIPTION OF EMBODIMENTS OF THE PRESENT INVENTION

[00023] The embodiments disclosed below are not intended to be exhaustive or limit the invention to the precise form disclosed in the following detailed description. Rather, the

embodiments are chosen and described so that others skilled in the art may utilize their teachings.

[00024] The present invention relates to an apparatus and method for filling pharmaceutical containers with a pharmaceutical. In **FIG.1**, a filling system **1000** comprises a container chamber **100** in communication with an ambient environment and a sealable chamber **200** adjoining the container chamber **100**, the sealable chamber **200** being capable of having an aseptic environment established within its interior and capable of maintaining that aseptic environment within its interior. The communication of chamber **100** with the ambient environment may be via a suitable access door **102**, schematically shown in broken outline in **FIG.1**. The ambient environment may be, for example, a clean room adapted for the handling of pharmaceuticals during production.

[00025] Chamber **200** shares with chamber **100** a transfer wall **280** and comprises an aseptically sealable port **220**. A variety of suitable port arrangements is contemplated. In some embodiments, port **220** is a simple door with an aseptic seal arrangement to ensure that chamber **200** maintains an aseptic condition. In other embodiments, port **220** may be a more complex door arrangement to ensure the aseptic condition in the interior of chamber **200**. In some embodiments, chamber **100** is completely open. This is the equivalent of there being no distinct first chamber **100**.

[00026] The interior of sealable chamber **200** may be rendered aseptic by any one or more of a number of treatments, including specifically treatments with sterilants, such as steam, hydrogen peroxide vapor, ozone, nitrogen dioxide, and ethylene oxide. The structures and mechanisms to perform such sterilization steps are well known in the art and, in the interest of clarity, are not shown in **FIG.1**.

[00027] The terms “aseptic” and “sterilize” and their derivatives are to be understood as follows for the purposes of the present specification. Establishing an aseptic condition in the

interior of a chamber shall be understood to mean establishing that condition throughout the internal atmosphere of the chamber as well as on substantially all exposed interior surfaces of the chamber. This shall include the surfaces of all items, containers, subsystems and the like exposed to the interior atmosphere of the chamber. The degree of sterilization may in some practical cases not be total. Extremely tight crevices or microcrevices may exist in the interior of the chamber, for example, such that a sterilizing gas or vapor may not perfectly penetrate into such tight regions. This is acknowledged both in the industry and in the standards set for industry.

[00028] As will be described below, some embodiments of the invention involve containers of which portions of their exterior surfaces are exposed to the internal atmosphere of a chamber. When the interior of the chamber is being sterilized, the portion of the surface of the container that is exposed to the internal atmosphere of the chamber is sterilized in the process. The action of establishing an aseptic condition within the interior of the chamber and “sterilizing the interior of the chamber” shall have the same meaning in this specification.

[00029] Introducing into the interior of a chamber with an aseptic condition an item of which the surfaces are not suitably sterilized destroys the existing aseptic condition within the chamber. Conversely, introducing an aseptic or sterilized item into an interior of a chamber that does not have an aseptic condition within that interior does not render that interior aseptic. In fact, all it does is to destroy the aseptic condition of the surface of the item so introduced. Similarly, introducing filtered air, even with all biological entities filtered out, into an unsterilized chamber does not in any way sterilize the chamber or render it aseptic to a degree acceptable in the pharmaceutical industry. The reason is that the interior surfaces of the chamber are not sterilized by the introduction of such air. All that is achieved is to contaminate the filtered air with active biological species resident on the interior surfaces of the unsterilized chamber.

[00030] In the interest of clarity and completeness, it should also be recorded that in the art the term “aseptic” is also sometimes used in association with the introduction of pharmaceutical fluids along aseptic tubes into bodies within controlled chambers. In such cases the term in the art refers to the condition inside the tube or to the fact that the pharmaceutical fluid may be filtered to a suitable degree. This in no way sterilizes or renders aseptic the interior of the chamber in question. The aseptic condition in such cases is confined to the interior of the tube bearing the pharmaceutical stream. Such streams are often filtered to a high degree, but such filtering affects only the interior of the particular tube and does not in any way sterilize the interior of the chamber.

[00031] In some prior art systems, containers introduced into a chamber for the purposes of being filled with a pharmaceutical are routed through sterilizing subsystems. This kills biological species on the containers. When such sterilized containers are introduced into the chamber when the chamber itself is not aseptic the containers lose their aseptic condition as biological species contained within the chamber will deposit on the previously aseptic containers.

[00032] Standards for clean rooms exist from both the United States Federal Government and ISO (International Standards Organization). These specify in great detail the allowed particulate content of a cubic volume of air in such a clean room facility. But none of these standards directly address the matter of biological species present on surfaces in the room. This serves to make the point that a chamber cannot be rendered aseptic by the management of its atmosphere or airflow only. Nor, conversely, can the chamber be rendered aseptic by the sterilization of only the surfaces of its interior. Rating a pharmaceutical or semiconductor clean room at any quality level, therefore, including “Class 100”, “Class 10” or “Class 1”, even when employing laminar flow hoods and the like or any quality of HEPA (High Efficiency Particulate Air) filters or ULPA (Ultra Low Particulate Air) filters, is not sufficient to assure an aseptic chamber at least because these standards do not provide for an assurable means to render the surfaces of the room sterile or aseptic.

[00033] The text “Guideline for Disinfection and Sterilization in healthcare Facilities, 2008” by Rutala et al from the Center for Disease Control lists a compendium of mechanisms and methods for sterilization. Our concern in this specification is specifically with those mechanisms for sterilizing the interior of a chamber; that is, sterilizing both the interior surfaces and the atmosphere within the chamber. Given the requirements, vapor base methods are most appropriate to the task. These include, but are not limited to, treatment with heated water vapor, hydrogen peroxide vapor, ozone, nitrogen dioxide, ethylene oxide, glutaraldehyde vapor or other suitable sterilizing gases and vapors. In one suitable method appropriate to the present invention, the sterilization is by means of hydrogen peroxide vapor which is then flushed using ozone before the chamber is employed in the filling of pharmaceutical containers.

[00034] Sealable chamber **200** may comprise in its interior a robotic rotary arm **260** mounted on a rotary stage **270**. Rotary stage **270** may also be an extensible stage so that robotic arm **260** may be raised and lowered vertically. Robotic rotary arm **260** may comprise two grips **262** and **264** disposed and configured for gripping a syringe **600** and for moving a plunger of the syringe **600** with respect to the cylinder of the syringe **600**. In **FIG.1**, grip **264** is disposed and configured to grip the plunger mechanism of syringe **600** and to move it with respect to the cylinder of syringe **600**, which is held stationary relative to robotic rotary arm **260** by grip **262**. By rotating rotary stage **270**, raising or lowering rotary stage **270**, and operating grip **264**, the syringe **600** may therefore be positioned anywhere on a cylindrical surface determined by a radius of robotic rotary arm **260** and the vertical adjustment range of rotary stage **270**, and the syringe **600** may be operated to perform an injection procedure or extraction procedure while so positioned. In other embodiments, robotic rotary arm **260** may be extensible to thereby allow syringe **600** to be positioned in a wider range of positions interior to the cylindrical surface defined by the maximum extendible radius of robotic rotary arm **260**. In the embodiment shown in **FIG.1**, robotic arm **260** is specifically a non-articulated robotic arm. To the extent that the present invention seeks simplicity and compactness, there is no restriction for robotic arm **260** to specifically emulate the human

arm in its articulation. Yet further robotic arm arrangements are contemplated and will be discussed later below.

[00035] Sealable chamber **200** may further comprise in its interior a syringe store. In the embodiment shown in **FIG. 1**, the syringe store is a carousel **230** mounted on a stage **232**. Carousel **230** is configured for holding a plurality of syringes **600** having syringe caps **620**. In some embodiments, stage **232** may be a vertically extensible stage bearing further carousels **230**. In such embodiments, stage **232** may be disposed and configured to raise and lower the carousel **230**. Carousel **230** is disposed in a position that allows robotic rotary arm **260** to collect and return syringes **600** from and to carousel **230**. To this end, carousel **230** is a rotary carousel allowing different ones of syringes **600** to be accessible to the grippers **262** and **264** of robotic rotary arm **260**.

[00036] Sealable chamber **200** may further comprise in its interior a syringe capping station **250**, disposed and arranged for robotic rotary arm **260** to engage syringes **600** with syringe capping station **250** to thereby remove syringe caps **620** from syringes **600** or to return syringe caps **620** to syringes **600** after the use of syringes **600**.

[00037] By way of example, rotary stage **270** may rotate arm **260** clockwise (looking down vertically in **FIG.1**) in order to collect a syringe **600** from carousel **230**, while rotary stage **270** may rotate arm **260** anti-clockwise (looking down vertically in **FIG.1**) in order to engage a syringe **600** with capping station **250** in order to remove a cap **620** from the syringe **600** and thereby expose hollow syringe needle **610**, for example a hypodermic needle.

[00038] Robotic arm **260** may be controlled by controller **700** in communication with robotic arm **260**. In **FIG. 1** controller **700** is shown as a distinct separate unit, but in other embodiments it may be incorporated into either chamber **100** or chamber **200**. Controller **700** may comprise a suitable computer or microcontroller with memory to store a software program and data provided by the operator. The operating of robotic arm **260** may comprise

the operating of rotary stage **270** and the operating of grips **262** and **264**. In some embodiments, controller **700** may also operate the sterilization facility not shown in **FIG. 1**. Controller **700** may further control the rotation of carousel **230** and stage **232**. Controller **700** may also control the sealing of chamber **200** and the pressure inside of chamber **200**. This allows the automation of the processes employed in system **1000**.

[00039] A variety of containers may be disposed within the interior of chamber **100**. In **FIG.1** the examples given are rigid pharmaceutical containers **510** of a first size, rigid pharmaceutical containers **530** of a second size, and intravenous (IV) bags **550**, being sealed to the transfer wall **280** by container sealing structures **520**, **540** and **560** respectively. Transfer wall **280** may have corresponding holes to allow access by needle **610** to the various containers while an aseptic condition is maintained in the interior of chamber **200**.

[00040] In **FIG.1** container sealing structures **520**, **540** and **560** are merely schematically indicated. **FIG 2(a)**, **(b)** and **(c)** show an exploded view, assembled view, and cross-section respectively of one example aseptic sealing structure **520** by which container **510**, for example, may be aseptically sealed to transfer wall **280** in order to give the needle **610** of syringe **600** access to the interior of the aseptically sealed container **510** without compromising the aseptic condition maintained in the interior of sealable chamber **200**. Sealing structure **540** may comprise a differently sized arrangement of the same design to seal container **530** to transfer wall **280**. In **FIG.1** two sizes of rigid pharmaceutical containers are shown. In general, fewer or more containers may be employed in chamber **100**.

[00041] In one example, shown in **FIG. 2(a)**, sealing structure **520** comprises flange structure **522** having a recessed portion with vapor communication holes **523**. Container **510**, aseptically sealed with a compressible pierceable closure **512**, for example a thermoplastic stopper, is placed upside down into the recessed portion of flange **522** with pierceable closure **512** over hole **521**. Cap **524** may then be placed over the upward facing bottom of the container **510** and tightened down onto flange **522** by means of bolts **526**. **FIG 2(b)** is an

isometric view of the completed arrangement of container **510** with closure **512** mounted in sealing structure **520**. **FIG. 2(c)** shows how container **510** is sealed aseptically to sealing structure **520** by means of o-rings **525** and the compressible pierceable closure **512**. Sealing structure may be aseptically sealed to transfer wall **280**, for example using o-rings **528** and suitable bolts (not shown).

[00042] When flange **522** is mounted to transfer wall **280**, the recessed portion of flange **522** extends into the interior of chamber **200**. Any gas or vapor employed to sterilize the interior of sealable chamber **200** may move through holes **523** in order to sterilize any portion of the exterior surface of container **510** that is accessible to sterilizing vapor or gas employed in the interior of sealable chamber **200**. In this specification the phrase “sterilizable portion” is used to describe that portion of the exterior surface of a pharmaceutical container aseptically sealed to the transfer wall **280** that is accessible to sterilizing vapor or gas employed to establish an aseptic condition in the interior of sealable chamber **200**.

[00043] With flange **522** mounted to transfer wall **280**, robotic rotary arm **260** may position and manipulate syringe **600** in order to pierce the pierceable closure **512** through hole **521** with hollow needle **610**. With the needle within the interior volume of container **512**, a portion of any fluid in syringe **600** may be injected into container **510**, or a portion of any fluid in container **512** may be extracted from container **510** into syringe **600** for use elsewhere.

[00044] **FIG. 2(d)** shows a container mounting plate **570** to which a plurality of container sealing structures **520** may be aseptically sealed in the same way, described above, as used to seal sealing structure **520** to transfer wall **280**. In this particular embodiment, plate **570** is aseptically sealed to transfer wall **280** by means of, for example without limitation, suitable o-rings and bolts (not shown). Transfer wall **280** may have corresponding holes to accommodate the plurality of pierceable closures **512** and flanges **522**.

[00045] One particularly useful type of pharmaceutical container is the intra-venous bag (IV-bag). FIG. 2(e) and FIG. 2(f) are isometric and cross-sectional views respectively of an example sealing structure **560** for the aseptic sealing of an IV-bag container **550** to transfer wall **280**. IV-bag tube **552** is aseptically sealed with pierceable closure **554**. Pierceable closure **554** may be aseptically sealed to flange **562** by means of o-ring **565**. Two half-annular caps **564** hold pierceable closure **554** to flange **562** by means of bolts **566**. Sealing structure **560** may be aseptically sealed to transfer wall **280** by means of o-ring **568** and bolts (not shown).

[00046] **FIG. 2(g)** shows a container mounting plate **580** to which a plurality of container sealing structures **560** may be aseptically sealed in the same way, described above, as used to seal sealing structure **560** to transfer wall **280**. In this particular embodiment, plate **580** is aseptically sealed to transfer wall **280** by means of, for example without limitation, suitable o-rings and bolts (not shown). Transfer wall **280** may have corresponding holes to accommodate the plurality of pierceable closures **554** and flanges **562**.

[00047] In embodiments where chamber **200** is absent, the fact that the invention allows for the pharmaceutical containers **510**, **530**, **550** to be mounted to transfer wall **480** under ambient conditions becomes particularly evident.

[00048] To ensure that atmosphere external to chamber **200** cannot leak into chamber **200**, chamber **200** is capable of operating under a positive pressure with respect to the environment outside chamber **200**. This aids in ensuring the aseptic condition inside chamber **200**.

[00049] A further embodiment of the apparatus of the invention is shown in and **FIG.3** in **which**, a filling system **2000** comprises a first chamber **300** in communication with an ambient environment and a second sealable chamber **400** adjoining the first chamber **300**, the second chamber **400** being capable of having an aseptic environment established within its

interior and capable of maintaining that aseptic environment within its interior. The communication of chamber **300** with the ambient environment may be via a suitable access door **302**, schematically shown in broken outline in **FIG.3**. The ambient environment may be, for example, a clean room adapted for the handling of pharmaceuticals during production.

[00050] Chamber **400** shares with chamber **300** a transfer wall **480** and comprises an aseptically sealable port **420**. A variety of suitable port arrangements is contemplated. In some embodiments, port **420** is a simple door with an aseptic seal arrangement to ensure that chamber **400** maintains an aseptic condition. In other embodiments, port **420** may be a more complex door arrangement to ensure the aseptic condition in the interior of chamber **400**. In some embodiments, chamber **300** is completely open. This is the equivalent of there being no distinct first chamber **300**. This emphasizes the point that the invention allows for the pharmaceutical containers **510**, **530**, **550** to be mounted to transfer wall **480** under ambient conditions.

[00051] The interior of chamber **400** may be rendered aseptic by any one or more of a number of treatments, including specifically treatment with steam, hydrogen peroxide vapor, ozone, nitrogen dioxide, and ethylene oxide. The structures and mechanisms to perform such sterilization steps are well known in the art and, in the interest of clarity, are not shown in **FIG. 3**.

[00052] Chamber **400** may comprise in its interior a robotic arm **460** mounted on a rotary stage **470**. Rotary stage **470** may also be an extensible stage so that robotic arm **460** may be raised and lowered vertically. Robotic arm **460** may be an articulated robotic arm comprising first **466** and second **468** arms that articulate with respect to each other about a common rotary elbow **469**. Robotic arm **460** may comprise two grips **462** and **464** disposed and configured for gripping a syringe **600** and for moving a plunger of the syringe **600** with respect to the cylinder of the syringe **600**. In **FIG. 3**, grip **464** is disposed and configured to grip the plunger mechanism of syringe **600** and to move it with respect to the cylinder of

syringe **600**, which is held stationary relative to arm **468** by grip **462**. By rotating rotary stage **470**, raising or lowering rotary stage **470**, articulating robotic arm **460**, and operating grip **264**, the syringe **600** may therefore be positioned over a wide range of positions in the interior of chamber **400**, and the syringe **600** may be operated to perform an injection procedure or extraction procedure while so positioned.

[00053] Chamber **400** may further comprise in its interior a syringe store **430** for holding a plurality of syringes **600** having syringe caps **620**. Syringe store **430** is disposed in a position that allows robotic arm **460** to collect and return syringes **600** from and to syringe store **430**.

[00054] Chamber **400** may further comprise in its interior a syringe capping station **450**, disposed and arranged for robotic rotary arm **460** to engage syringes **600** with syringe capping station **450** to thereby remove caps **620** from syringes **600** to thereby expose hollow syringe needle **610**, for example a hypodermic needle, or to return caps **620** to syringes **600** after the use of syringes **600**.

[00055] Robotic arm **460** may be controlled by controller **800** in communication with robotic arm **460**. In **FIG. 3** controller **800** is shown as a distinct separate unit, but in other embodiments it may be incorporated into either chamber **300** or chamber **400**. Controller **800** may comprise a suitable computer or microcontroller with a memory to store a software program and data provided by the operator. The operating of robotic arm **460** may comprise the operating of rotary stage **470** and the operating of grips **462** and **464**. In some embodiments, controller **800** may also operate the sterilization facility not shown in **FIG. 3**. Controller **800** may also control the sealing of chamber **400** and the pressure inside of chamber **400**. This allows the automation of the processes employed in system **2000**.

[00056] A variety of containers may be disposed within the interior of chamber **300**. In **FIG.3** the examples given are rigid pharmaceutical containers **510** of a first size, rigid pharmaceutical containers **530** of a second size, and intravenous (IV) bags **550**. As shown in

FIG. 3, a plurality of containers **510** may be aseptically sealed to container mounting plate **570** as already described, and container mounting plate **570** may then be aseptically sealed to transfer wall **480**. As shown in **FIG. 3**, the same arrangement may be made with respect to differently sized rigid containers **530** and container mounting plate **590**. A plurality of IV-bags **550** may be aseptically sealed to container mounting plate **580** as already described, and container mounting plate **580** may then be aseptically sealed to transfer wall **480**. In an alternative embodiment, these containers **510**, **530** and **550** may be aseptically sealed directly to transfer wall **480** in exactly the same way (not shown in **FIG. 3**) as they are described above to be sealed to transfer wall **280**. The use of an articulated arm **460** allows the linearly arranged containers to be easily accessed by syringe **600**. Transfer wall **480** may have corresponding holes to allow access by needle **610** to the various containers while an aseptic condition is maintained in the interior of chamber **400**.

[00057] Robotic rotary arm **460** may position and manipulate syringe **600** in order to pierce the pierceable closure **512** through hole **521** with hollow needle **610**. With the needle within the interior volume of container **512**, a portion of any fluid in syringe **600** may be injected into container **510**, or a portion of any fluid in container **512** may be extracted from container **510** into syringe **600** for use elsewhere.

[00058] To ensure that atmosphere external to chamber **400** cannot leak into chamber **400**, chamber **400** is capable of operating under a positive pressure with respect to the environment outside chamber **400**. This aids in ensuring the aseptic condition inside chamber **400**. The filter and pump systems required to establish such positive pressure are well understood by those skilled in the art and will not be dwelt upon in this specification.

[00059] In a further aspect described at the hand of the flow chart of **FIG.4**, a method **[3000]** is provided for filling pharmaceutical containers with a fluid pharmaceutical product. The method **[3000]** comprises: providing **[3100]** an aseptically sealable chamber **200,400** comprising a robotic arm **260,460** and a transfer wall **280,480** capable of having aseptically

mounted thereto a plurality of pharmaceutical containers **510,530,550** pre-sealed with pierceable closures **512,554**; aseptically mounting **[3200]** to the transfer wall **280,480** a plurality of receiving pharmaceutical containers **510,530,550** aseptically pre-sealed with corresponding pierceable closures **512,554**; providing **[3300]** within the sealable chamber **200,400** a first pharmaceutical syringe **600** comprising a first syringe needle **610** and containing a first fluid pharmaceutical product; aseptically sealing **[3400]** the sealable chamber **200,400**; establishing **[3500]** an aseptic condition within the interior of the sealable chamber **200,400** and on all portions of the plurality of receiving pharmaceutical containers **510,530,550** exposed to the interior of the sealable chamber **200,400**; piercing **[3600]** the pierceable closure **512,554** of at least one of the receiving containers **510,530,550** with the first syringe needle **610**; and injecting **[3700]** a portion of the product from the first syringe **600** into the at least one receiving container **510,530,550** through the closure **512,554** via the first syringe needle **610**. The providing **[3100]** an aseptically sealable chamber **200,400** may comprise providing an aseptically sealable chamber **200,400** comprising an articulated robotic arm **260,460** and the injecting **[3700]** may comprise operating the articulated robotic arm **260,460**.

[00060] The providing **[3300]** a first syringe **600** within the sealable chamber **200,400** may comprise: aseptically mounting to the transfer wall **280,480** a first source pharmaceutical container containing the first fluid pharmaceutical product and aseptically pre-sealed with a corresponding pierceable closure wherein the mounting of the first source container comprises disposing the first source container in a location and orientation wherein its associated closure is penetrable from within the interior of the sealable chamber **200,400**; piercing the associated closure with the first syringe needle **610**; and extracting a portion of the first fluid pharmaceutical product from the first source pharmaceutical container into the first pharmaceutical syringe **600**.

[00061] At least one of the aseptically sealing **[3400]**, the establishing an aseptic condition **[3500]**, the piercing **[3600]**, the injecting **[3700]**, and the extracting a portion of the first fluid pharmaceutical product is performed automatically. The method may further comprise

establishing within the sealable chamber **200,400** a positive atmospheric pressure and establishing the pressure may be performed automatically after the aseptically sealing **[3400]** the sealable chamber **200,400**.

[00062] The method may further comprise: second injecting a portion of a second fluid pharmaceutical product from a second syringe into the at least one of the plurality of receiving pharmaceutical containers through the corresponding pierceable closure via an associated second syringe needle. The providing **[3100]** an aseptically sealable chamber **200,400** may comprise providing an aseptically sealable chamber **200,400** comprising a syringe store **230,430** and the second injecting may comprise: aseptically mounting to the transfer wall a second source pharmaceutical container aseptically pre-sealed with a corresponding pierceable closure and containing the second fluid pharmaceutical wherein the mounting of the second source pharmaceutical container comprises disposing the second source pharmaceutical container in a location and orientation wherein the second source pharmaceutical container closure is penetrable from within the interior of the sealable chamber **200,400**; operating the robotic arm **260,460** to place the first syringe in the syringe store **230,430**; operating the robotic arm **260,460** to obtain from the syringe store **230,430** the second pharmaceutical syringe comprising the second syringe needle; operating the robotic arm **260,460** to pierce the closure of the second source pharmaceutical container with the second syringe needle; and operating the robotic arm **260,460** to extract a portion of the second fluid pharmaceutical product from the second source pharmaceutical container into the syringe.

[00063] The establishing an aseptic condition may comprise treating the interior of the sealable chamber **200,400** and all portions of the at least one receiving pharmaceutical container exposed to the interior of the sealable chamber **200,400** with at least one of heated water vapor, gaseous hydrogen peroxide, ozone, nitrogen dioxide, ethylene oxide and glutaraldehyde vapor.

[00064] Systems according to the invention can allow a variety of dispensing operations, including but not limited to pharmaceutical compounding operations. Different amounts of an active ingredient can be extracted from a source container and added to receiving containers that are prefilled with an inactive ingredient, for example, allowing the different receiving containers to hold different doses of an active ingredient. Different active and/or inactive ingredients can also be extracted from two or more different source containers and added to one or more receiving containers, allowing more complex formulations. Depending on the selected sequencing for a particular dispensing operation, the system may need to switch syringes to avoid cross contamination.

[00065] The system described above has been implemented in connection with special-purpose software running on a general-purpose computer platform, but the underlying logic could also be embodied in whole or in part using special-purpose hardware. And while the system can be broken into the series of modules and steps shown for illustration purposes, one of ordinary skill in the art would recognize that it is also possible to combine them and/or split them differently to achieve a different breakdown, and that the functions of such modules and steps can be arbitrarily distributed and intermingled within different entities, such as routines, files, and/or machines. Moreover, different providers can develop and operate different parts of the system.

[00066] Embodiments of the present invention addresses the need for compact small scale filling and dispensing of fluid pharmaceuticals and confines only essential aseptic subsystems to an aseptic chamber, whilst making it possible to handle aseptically sealed pharmaceutical containers in the ambient environment outside the aseptic chamber.

[00067] While this invention has been described as having an exemplary design, the present invention may be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the invention using its general principles. Further, this application is intended to cover such departures

from the present disclosure as come within known or customary practice in the art to which this invention pertains.

What is claimed is:

1. A system for aseptically filling pharmaceutical containers with pharmaceutical fluid, the system comprising:

an aseptically sealable chamber,

wherein the aseptically sealable chamber includes a transfer wall including a plurality of openings each providing a sealing surface being aseptically sealable to a container,

a robotic arm disposed within the sealable chamber and having a range of motion that allows it to move a fluid transfer conduit to each of the openings,

a fluid transfer actuator to drive fluid through the fluid transfer conduit,

a controller that includes:

three-dimensional arm control logic to move the fluid transfer conduit to a selected container that sealably passes through one of the openings, and

fluid transfer actuation logic to operate the fluid transfer actuator to transfer fluid between a fluid transfer vessel and the selected container, and

a sterilizing facility for establishing an aseptic condition within the sealable chamber.

2. The system of claim 1 wherein the fluid transfer conduit is a syringe needle mounted on a syringe that includes a body and a plunger and wherein the fluid transfer actuator is a linear actuator that moves the plunger relative to the body.

3. The system of claim 2 further including at least one container with a pierceable closure sealably passing through one of the openings with the pierceable closure positioned

inside the sealable chamber and wherein the three-dimensional arm control logic is operative to cause the syringe needle to pierce the pierceable closure.

4. The system of claim 3, wherein the three-dimensional arm control logic and the fluid transfer actuation logic are operative to transfer fluids from one container to another.

5. The system of claim 3, further comprising a syringe store disposed in the interior of the sealable chamber and wherein the three-dimensional arm control logic is operative to transfer syringes to and from the syringe store.

6. The system of claim 1, wherein the robotic arm is an articulated robotic arm.

7. The system of claim 1, wherein the sealable chamber is capable of being operated under a positive pressure when sealed.

8. A method for filling pharmaceutical containers with a fluid pharmaceutical product, the method comprising:

providing an aseptically sealable chamber comprising a robotic arm and a transfer wall capable of having aseptically mounted thereto a plurality of pharmaceutical containers pre-sealed with pierceable closures, wherein the aseptically sealable chamber is capable of maintaining an aseptic condition within an interior of the sealable chamber when the pharmaceutical containers are mounted to the transfer wall,

aseptically mounting to the transfer wall a plurality of pharmaceutical containers aseptically pre-sealed with corresponding pierceable pharmaceutical container closures, wherein the mounting of the plurality of pharmaceutical containers comprises mounting the plurality of pharmaceutical containers in locations and orientations wherein the corresponding pierceable pharmaceutical container closures are penetrable from within the interior of the sealable chamber,

providing within the sealable chamber a first pharmaceutical syringe comprising a first syringe needle,

aseptically sealing the sealable chamber,

establishing an aseptic condition within the interior of the sealable chamber and on all portions of the plurality of pharmaceutical containers exposed to the interior of the sealable chamber, and

transferring a portion of the first fluid pharmaceutical product between the first syringe and at least one of the plurality of pharmaceutical containers through the corresponding pierceable pharmaceutical container closure via the first syringe needle.

9. The method of claim 8, wherein the transferring comprises piercing the corresponding pierceable pharmaceutical container closure with the first syringe needle.

10. The method of claim 8, wherein the transferring comprises operating the robotic arm.

11. The method of claim 8, wherein providing an aseptically sealable chamber comprising a robotic arm comprises providing an aseptically sealable chamber comprising an articulated robotic arm and the transferring comprises operating the articulated robotic arm.

12. The method of claim 8, wherein the transferring includes injecting a portion of the first pharmaceutical product into the one of the plurality of pharmaceutical containers, and wherein providing within the sealable chamber the first pharmaceutical syringe containing the first fluid pharmaceutical product comprises:

aseptically mounting to the transfer wall a first source pharmaceutical container aseptically pre-sealed with a corresponding pierceable first pharmaceutical container closure, wherein the mounting of the first source pharmaceutical container comprises disposing the first source pharmaceutical container in a location and orientation wherein the first pharmaceutical container closure is penetrable from within the interior of the sealable chamber,

piercing the closure of the first source pharmaceutical container with the first syringe needle, and

extracting a portion of the first fluid pharmaceutical product from the first source pharmaceutical container into the first pharmaceutical syringe.

13. The method of claim 12, wherein at least one of the aseptically sealing, the establishing an aseptic condition, the transferring, and the extracting a portion of the first fluid pharmaceutical product is performed automatically.

14. The method of claim 12, further comprising establishing within the sealable chamber a positive atmospheric pressure.

15. The method of claim 14, wherein the establishing within the sealable chamber a positive atmospheric pressure is performed automatically after the aseptically sealing the sealable chamber.

16. The method of claim 12, further comprising
injecting a portion of a second fluid pharmaceutical product from a second syringe into the at least one of the plurality of pharmaceutical containers through the corresponding pierceable pharmaceutical container closure via a second syringe needle.

17. The method of claim 16, wherein the providing an aseptically sealable chamber comprises providing an aseptically sealable chamber comprising a syringe store, and wherein the second syringe is prepared by:

aseptically mounting to the transfer wall a second source pharmaceutical container aseptically pre-sealed with a corresponding pierceable second pharmaceutical container closure and containing the second fluid pharmaceutical, wherein the mounting of the second source pharmaceutical container comprises disposing the second source pharmaceutical container in a location and orientation wherein the second pharmaceutical container closure is penetrable from within the interior of the sealable chamber,

operating the robotic arm to place the first syringe in the syringe store,

operating the robotic arm to obtain from the syringe store the second pharmaceutical syringe comprising the second syringe needle,

operating the robotic arm to pierce the closure of the second source pharmaceutical container with the second syringe needle, and

operating the robotic arm to extract a portion of the second fluid pharmaceutical product from the second source pharmaceutical container into the syringe.

18. The method of claim 8, wherein the establishing an aseptic condition comprises treating the interior of the sealable chamber and all portions of the at least one pharmaceutical container exposed to the interior of the sealable chamber with at least one of heated water vapor, gaseous hydrogen peroxide, ozone, nitrogen dioxide, ethylene oxide, and glutaraldehyde vapor.

19. A system for aseptically filling pharmaceutical containers with pharmaceutical fluid, the system comprising:

means for receiving a plurality of containers while exposing accessible parts of the containers,

means for transferring pharmaceutical fluid to and from the containers through the accessible parts of the containers,

means for reaching the accessible parts of the received containers with the means for transferring,

means for controlling the means for reaching and the means for transferring,

means for together isolating the exposed parts of the containers, the means for reaching, and the means for transferring, and

means for sterilizing the exposed parts of the containers, the means for reaching, and the means for transferring.

1/5








Fig. 1

2/5



3/5



4/5




Fig. 3

5/5




Fig. 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2017/001183

A. CLASSIFICATION OF SUBJECT MATTER

IPC: **B65B 3/04** (2006.01) , **A61J 1/20** (2006.01) , **B65B 55/00** (2006.01) , **A61J 1/06** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: B65B 3/04; A61J 1/20; B65B 55/00; A61J 1/06 (2006.01).

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Databases: Orbit, Canadian Patent Database

Keywords: container, pharmaceutic+ , container, filling, aseptic+, pierce+, chamber, syringe, needle, robot+, sealable, wall.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CA2921554A1 (GOLD et al.) 19 February 2015 (19-02-2015)	1-19
A	US2013180618A1 (PY) 18 July 2013 (18-07-2013)	1-19
A	US2010236193A1 (PY et al.) 23 September 2010 (23-09-2010)	1-19
A	US2006231519A1(PY et al.) 19 October 2006 (19-10-2006)	1-19
A	US5979515A (OLSSON) 09 November 1999 (09-11-1999)	1-19
A	US5799464A (OLSSON) 01 September 1998 (01-09-1998)	1-19

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* "A" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	--	--------------------------	--

Date of the actual completion of the international search
20 December 2017 (20-12-2017)Date of mailing of the international search report
12 January 2018 (12-01-2018)Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 819-953-2476

Authorized officer

Ciprian Galasiu (819) 639-5781

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IB2017/001183

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
CA2921554A1	19 February 2015 (19-02-2015)	CA2921554A1 EP3033276A2 EP3033276A4 TW201521711A US2016200461A1 US2016272347A1 WO2015023924A2 WO2015023924A3	19 February 2015 (19-02-2015) 22 June 2016 (22-06-2016) 12 April 2017 (12-04-2017) 16 June 2015 (16-06-2015) 14 July 2016 (14-07-2016) 22 September 2016 (22-09-2016) 19 February 2015 (19-02-2015) 07 May 2015 (07-05-2015)
US2013180618A1	18 July 2013 (18-07-2013)	US2013180618A1 US9801787B2 CA2862241A1 CN104334213A EP2804645A1 EP2804645A4 EP2804645B1 IN6816DEN2014A JP2015503994A JP6129208B2 KR20140125793A KR101740238B1 MX2014008698A RU2014133741A RU2618474C2 WO2013109794A1	18 July 2013 (18-07-2013) 31 October 2017 (31-10-2017) 25 July 2013 (25-07-2013) 04 February 2015 (04-02-2015) 26 November 2014 (26-11-2014) 03 June 2015 (03-06-2015) 12 April 2017 (12-04-2017) 22 May 2015 (22-05-2015) 05 February 2015 (05-02-2015) 17 May 2017 (17-05-2017) 29 October 2014 (29-10-2014) 26 May 2017 (26-05-2017) 09 March 2015 (09-03-2015) 10 March 2016 (10-03-2016) 03 May 2017 (03-05-2017) 25 July 2013 (25-07-2013)
US2010236193A1	23 September 2010 (23-09-2010)	US2010236193A1 US7992597B2 AR040057A1 AR044434A2 AU2001247981B2 AU2001247981C1 AU2001247981C9 AU2003299041A1 AU2003299041B2 AU2004207233A1 AU2004207233B2 AU2004207233C1 AU2006202172A1 AU2006202172B2 BR0116879A BR0116879B1 BR0313992A BRPI0313992B1 BRPI0407067A CA2449704A1 CA2497664A1 CA2497664C CA2514058A1 CA2514058C CN1745019A CN100526165C CN101001782A CN101596962A CN101596962B	23 September 2010 (23-09-2010) 09 August 2011 (09-08-2011) 16 March 2005 (16-03-2005) 14 September 2005 (14-09-2005) 23 February 2006 (23-02-2006) 09 November 2006 (09-11-2006) 16 November 2006 (16-11-2006) 08 April 2004 (08-04-2004) 05 June 2008 (05-06-2008) 12 August 2004 (12-08-2004) 09 August 2007 (09-08-2007) 24 April 2008 (24-04-2008) 15 June 2006 (15-06-2006) 02 September 2010 (02-09-2010) 17 February 2004 (17-02-2004) 29 May 2012 (29-05-2012) 02 August 2005 (02-08-2005) 21 July 2015 (21-07-2015) 17 January 2006 (17-01-2006) 22 August 2002 (22-08-2002) 01 April 2004 (01-04-2004) 18 November 2008 (18-11-2008) 12 August 2004 (12-08-2004) 13 May 2014 (13-05-2014) 08 March 2006 (08-03-2006) 12 August 2009 (12-08-2009) 18 July 2007 (18-07-2007) 09 December 2009 (09-12-2009) 23 March 2011 (23-03-2011)

[X] continued on page 4

[X] continuation of page 3

CN102145774A	10 August 2011 (10-08-2011)
EG23148A	31 May 2004 (31-05-2004)
EP1370471A1	17 December 2003 (17-12-2003)
EP1370471A4	18 February 2009 (18-02-2009)
EP1537020A2	08 June 2005 (08-06-2005)
EP1537020A4	27 January 2010 (27-01-2010)
EP1590437A2	02 November 2005 (02-11-2005)
EP1590437A4	18 June 2008 (18-06-2008)
EP1594749A2	16 November 2005 (16-11-2005)
EP1594749A4	28 October 2009 (28-10-2009)
EP1594749B1	29 May 2013 (29-05-2013)
HK1065010A1	05 September 2014 (05-09-2014)
HK1139635A1	30 December 2011 (30-12-2011)
HK1160827A1	09 May 2014 (09-05-2014)
HK1198530A1	15 May 2015 (15-05-2015)
IL157269A	17 February 2010 (17-02-2010)
IL157269D0	19 February 2004 (19-02-2004)
IL167224A	01 September 2009 (01-09-2009)
IL169804A	30 November 2010 (30-11-2010)
IL186251D0	20 January 2008 (20-01-2008)
IL186251A	29 April 2010 (29-04-2010)
JP2004533971A	11 November 2004 (11-11-2004)
JP4010948B2	21 November 2007 (21-11-2007)
JP2006516906A	13 July 2006 (13-07-2006)
JP4401355B2	20 January 2010 (20-01-2010)
JP2006517110A	20 July 2006 (20-07-2006)
JP4425140B2	03 March 2010 (03-03-2010)
JP2010005461A	14 January 2010 (14-01-2010)
JP5106509B2	26 December 2012 (26-12-2012)
JP2009149378A	09 July 2009 (09-07-2009)
JP5123237B2	23 January 2013 (23-01-2013)
JP2009291640A	17 December 2009 (17-12-2009)
JP2015051375A	19 March 2015 (19-03-2015)
KR20040011462A	05 February 2004 (05-02-2004)
KR100641464B1	31 October 2006 (31-10-2006)
KR20050073450A	13 July 2005 (13-07-2005)
KR100644331B1	10 November 2006 (10-11-2006)
MXPA03007195A	19 April 2005 (19-04-2005)
MXPA05002458A	30 September 2005 (30-09-2005)
MXPA05008098A	08 February 2006 (08-02-2006)
MY129847A	31 May 2007 (31-05-2007)
MY140836A	29 January 2010 (29-01-2010)
NO20051624A	01 April 2005 (01-04-2005)
NZ527817A	27 August 2004 (27-08-2004)
NZ538754A	30 April 2010 (30-04-2010)
NZ595341A	30 May 2014 (30-05-2014)
PL365645A1	10 January 2005 (10-01-2005)
PL209749B1	31 October 2011 (31-10-2011)
PL209835B1	31 October 2011 (31-10-2011)
PL375626A1	12 December 2005 (12-12-2005)
PL209835B1	31 October 2011 (31-10-2011)
PL375626A1	12 December 2005 (12-12-2005)
RU2005123708A	10 June 2006 (10-06-2006)
RU2376220C2	20 December 2009 (20-12-2009)
RU2005106199A	10 June 2006 (10-06-2006)
RU2531451C2	20 October 2014 (20-10-2014)

[X] continued on page 5

[X] continuation of page 4

SG146436A1	30 October 2008 (30-10-2008)
TW561043B	11 November 2003 (11-11-2003)
US2002023409A1	28 February 2002 (28-02-2002)
US6604561B2	12 August 2003 (12-08-2003)
US2003159750A1	28 August 2003 (28-08-2003)
US6684916B2	03 February 2004 (03-02-2004)
US2004083686A1	06 May 2004 (06-05-2004)
US2008066824A1	20 March 2008 (20-03-2008)
US7445033B2	04 November 2008 (04-11-2008)
US7490639B2	17 February 2009 (17-02-2009)
US2008053561A1	06 March 2008 (06-03-2008)
US7500498B2	10 March 2009 (10-03-2009)
US2004214212A1	28 October 2004 (28-10-2004)
US7638270B2	29 December 2009 (29-12-2009)
US2005217211A1	06 October 2005 (06-10-2005)
US7669390B2	02 March 2010 (02-03-2010)
US2005223677A1	13 October 2005 (13-10-2005)
US7707807B2	04 May 2010 (04-05-2010)
US2007000573A1	04 January 2007 (04-01-2007)
US7726352B2	01 June 2010 (01-06-2010)
ZA200306226B	12 August 2004 (12-08-2004)
ZA200502121B	30 January 2008 (30-01-2008)

US2006231519A1	19 October 2006 (19-10-2006)	US7954521B2	07 June 2011 (07-06-2011)
		AU2006332049A1	23 August 2007 (23-08-2007)
		AU2006332049A2	23 August 2007 (23-08-2007)
		AU2006332049A8	05 March 2009 (05-03-2009)
		BRPI0607233A2	25 August 2009 (25-08-2009)
		CA2602222A1	25 July 2006 (25-07-2006)
		CA2602222C	28 November 2017 (28-11-2017)
		CN101535146A	16 September 2009 (16-09-2009)
		CN104477496A	01 April 2015 (01-04-2015)
		EP1888424A2	20 February 2008 (20-02-2008)
		EP1888424A4	21 September 2016 (21-09-2016)
		MX2007008927A	21 October 2009 (21-10-2009)
		RU2395440C2	27 July 2010 (27-07-2010)
		US2011052768A1	03 March 2011 (03-03-2011)
		US8132600B2	13 March 2012 (13-03-2012)
		US2012186697A1	26 July 2012 (26-07-2012)

US5979515A	09 November 1999 (09-11-1999)	US5979515A	09 November 1999 (09-11-1999)
		AT266993T	15 June 2004 (15-06-2004)
		AU6949696A	27 March 1997 (27-03-1997)
		AU700700B2	14 January 1999 (14-01-1999)
		BR9606632A	16 September 1997 (16-09-1997)
		CA2203252A1	13 March 1997 (13-03-1997)
		N1121198C	17 September 2003 (17-09-2003)
		CZ9701317A3	15 October 1997 (15-10-1997)

[X] continued on page 6

[X] continuation of page 5

DE69632528D1	24 June 2004 (24-06-2004)
DE69632528T2	12 May 2005 (12-05-2005)
EP0812177A1	17 December 1997 (17-12-1997)
EP0812177B1	19 May 2004 (19-05-2004)
ES2219695T3	01 December 2004 (01-12-2004)
HU9801286A2	28 September 1998 (28-09-1998)
HU9801286A3	28 April 2000 (28-04-2000)
IL120692D0	14 August 1997 (14-08-1997)
IL120692A	21 November 2000 (21-11-2000)
IL129505A	24 July 2001 (24-07-2001)
IL129505D0	29 February 2000 (29-02-2000)
IS4465A	17 April 1997 (17-04-1997)
JPH10508817A	02 September 1998 (02-09-1998)
JP4087901B2	21 May 2008 (21-05-2008)
KR100431230B1	04 August 2004 (04-08-2004)
MX9703338A	31 July 1997 (31-07-1997)
NO971987A	29 April 1997 (29-04-1997)
NO971987D0	29 April 1997 (29-04-1997)
NO313321B1	16 September 2002 (16-09-2002)
NZ318109A	28 January 1999 (28-01-1999)
PL320349A1	29 September 1997 (29-09-1997)
PT812177E	30 September 2004 (30-09-2004)
RU2179011C2	10 February 2002 (10-02-2002)
SE9503102D0	08 September 1995 (08-09-1995)
SK53497A3	14 January 1998 (14-01-1998)
TR9700335T1	21 August 1998 (21-08-1998)
US5799464A	01 September 1998 (01-09-1998)
WO9709026A1	13 March 1997 (13-03-1997)

US5799464A	01 September 1998 (01-09-1998)	US5799464A	01 September 1998 (01-09-1998)
		AT266993T	15 June 2004 (15-06-2004)
		AU6949696A	27 March 1997 (27-03-1997)
		AU700700B2	14 January 1999 (14-01-1999)
		BR9606632A	16 September 1997 (16-09-1997)
		CA2203252A1	13 March 1997 (13-03-1997)
		CA2203252C	17 April 2007 (17-04-2007)
		CN1164827A	12 November 1997 (12-11-1997)
		CN1121198C	17 September 2003 (17-09-2003)
		CZ9701317A3	15 October 1997 (15-10-1997)
		DE69632528D1	24 June 2004 (24-06-2004)
		DE69632528T2	12 May 2005 (12-05-2005)
		DK0812177T3	16 August 2004 (16-08-2004)
		EE9700111A	15 December 1997 (15-12-1997)
		EP0812177A1	17 December 1997 (17-12-1997)
		EP0812177B1	19 May 2004 (19-05-2004)
		ES2219695T3	01 December 2004 (01-12-2004)
		HU9801286A2	28 September 1998 (28-09-1998)
		HU9801286A3	28 April 2000 (28-04-2000)
		IL120692D0	14 August 1997 (14-08-1997)
		IL120692A	21 November 2000 (21-11-2000)
		IL129505A	24 July 2001 (24-07-2001)
		IL129505D0	29 February 2000 (29-02-2000)
		IS4465A	17 April 1997 (17-04-1997)
		JPH10508817A	02 September 1998 (02-09-1998)
		JP4087901B2	21 May 2008 (21-05-2008)

[X] continued on page 7

[X] continuation of page 6

NO971987A	29 April 1997 (29-04-1997)
KR100431230B1	04 August 2004 (04-08-2004)
MX9703338A	31 July 1997 (31-07-1997)
NO971987D0	29 April 1997 (29-04-1997)
NO313321B1	16 September 2002 (16-09-2002)
NZ318109A	28 January 1999 (28-01-1999)
PL320349A1	29 September 1997 (29-09-1997)
PT812177E	30 September 2004 (30-09-2004)
RU2179011C2	10 February 2002 (10-02-2002)
SE9503102D0	08 September 1995 (08-09-1995)
SK53497A3	14 January 1998 (14-01-1998)
TR9700335T1	21 August 1998 (21-08-1998)
US5979515A	09 November 1999 (09-11-1999)
WO9709026A1	13 March 1997 (13-03-1997)